The CAROLINA trial
CAROLINA provided some much-needed clarity on the cardiovascular safety of sulfonylureas, showing that glimepiride had an equivalent cardiovascular safety to linagliptin – a dipeptidyl peptidase-4 inhibitor with an established neutral cardiovascular safety profile.
The CAROLINA investigators will provide a comprehensive overview of their findings to date at the 55th EASD Annual Meeting (EASD 2019):
Results and implications of CAROLINA (CARdiOvascular Safety of LINAgliptin) comparing linagliptin vs glimepiride
Thursday, September 19, 13:15–14:15, Ochoa Hall, Fira Barcelona Gran Via, Spain
Session Chair: J. Rosenstock, USA
- Introduction and study background. J. Rosenstock, USA
- Study design and baseline characteristics. M. Espeland, USA
- Metabolic and weight outcomes. S .E. Kahn, USA
- Cardiovascular, mortality and hospitalisation outcomes. N. Marx, Germany
- Safety and comprehensive hypoglycaemia analyses. B. Zinman, Canada
- Clinical implications. D. K. McGuire, USA
- Commentary. P. D. Home, UK
What our Editorial Board said:
Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).